

PARTNERSHIPS SCIENCE SOLUTIONS




2015 ANNUAL REVIEW

JANUARY

Innovative Precision Medicine Trial, Lung-MAP, Expands Across Nation

More than 700 sites activated 210 patients enrolled



Friends Plays Key Role in House 21st Century Cures Act

February 23, 2015 – *Friends* holds congressional briefing on 21st Century Cures Act

May 21, 2015 – House Energy & Commerce Committee unanimously passes bill

July 10, 2015 - Bill passes House















May 19, 2015 – *Friends* Creates Momentum for Enhancing Patient Input and Regulatory Innovation

Leaders from advocacy, industry, science, academia and government discuss pressing issues with FDA leadership and develop framework for patient input







JUNE

June 10, 2015 – *Friends* Convenes Multi-stakeholder Forum Exploring Rate-limiting Steps in Manufacturing Readiness for Breakthrough Drug Development

September 9, 2015 – *Friends* Charts Blueprint for Personalized Medicine

Friends partners with Alexandria Real Estate Equities to host forum addressing how genetic databases alter research



FRIENDS of CANCER RESEARCH



SEPTEMBER



OCTOBER

October 22, 2015 – *Friends* Celebrates Incredible Leaders, Accomplishments

Friends honors Marlene Malek, Rep. Diana DeGette (D-CO) and Rep. Fred Upton (R-MI) at 19th Annual Cancer Leadership Awards Reception; NIH Dir. Francis Collins surprises attendees through song "If Not Now, Tell Me When"



November 12, 2015 – *Friends* Partners with Prevision Policy to Launch Biopharma Congress

Keynotes delivered by CMS Acting Administrator Andy Slavitt and FDA CDER Dir. Janet Woodcock; Former FDA Commissioners Margaret Hamburg and Mark McClellan discuss future of FDA with Ellen Sigal

November 17, 2015 – 8th *Friends*-Brookings Annual Meeting

Califf makes first appearance post-Senate confirmation hearing; meeting sought recommendations to:

- Integrate new measures of tumor response into drug development programs
- Develop a framework to improve use of expansion cohorts to support drug approvals
- Facilitate incorporation of patient reported outcomes into drug development and support improved collaboration between government and sponsors



Breakthrough Continues to Revolutionize Drug Development


Friends was pivotal in creating the designation, moving it from an idea to reality in just 13 months. Since the program began there have been:

- 384 breakthrough therapy designation requests
- 118 designations granted
- 39 FDA approvals
- 30 approvals for novel indications

Within the last year there were:

- 34 cancer drugs that received the designation
- 21 breakthrough cancer drugs approved

Breakthrough Designations by Therapeutic Categories



About Friends

Friends of Cancer Research (*Friends*) drives collaboration among partners from every healthcare sector to power advances in science, policy and regulation that speed life-saving treatments to patients.

During the past 20 years, *Friends* has been instrumental in the creation and implementation of policies ensuring patients receive the best treatments in the fastest and safest way possible. We've been successful to date due to our ability to convene the right people at the right time and put forth revolutionary, yet realistic ideas.

As we embark on this milestone year, we look forward to continuing this critical work with our trusted partners and continue to lead the way in evolving cancer research and treatment.

2015 Publications

The articles below were created either entirely by or with input from Friends of Cancer Research and published in 2015.

The role of nonrandomized trials in the evaluation of oncology drugs. Clinical Pharmacology and Therapeutics, May 2015.

Improving evidence developed from populationlevel experience with targeted agents. Clinical Pharmacology and Therapeutics, May 2015.

Modernizing Measurement of Tumor Response to Therapy: Application to Immunotherapeutics. 2015 Conference on Clinical Cancer Research.

Capturing Symptomatic Adverse Events From the Patients' Perspective: The Potential Role of the National Cancer Institute's PRO-CTCAE Measurement System. 2015 Conference on Clinical Cancer Research.

The Blurring of Phase 1, 2 and 3 Trials in Oncology: Expansion Cohorts in Phase 1 Trials. 2015 Conference on Clinical Cancer Research.

Examining Manufacturing Readiness for Breakthrough Drug Development. American Association of Pharmaceutical Scientists. PharmSciTech, November 2015.

Enhancing Use of Patient-Centered Data in Regulatory Decision-Making. Friends of Cancer Research and Burroughs Wellcome Fund. 2015.

Regulatory decision-making meets the real world. Science Translational Medicine, November 2015.

Friends Board of Directors

EXECUTIVE COMMITTEE

Ellen V. Sigal, Ph.D.

Chair & Founder, Friends of Cancer Research

Marlene Malek, R.N.

President, Friends of Cancer Research

Barbara Duffy Stewart, M.P.H.

Executive Director, Association of American Cancer Institutes

Sudip S. Parikh, Ph.D.

Vice President & General Manager, Health & Analytics, Battelle Memorial Institute

Margaret Foti, Ph.D., M.D. (h.c.)

Chief Executive Officer, American Association for Cancer Research

Jonathan Leff

Partner, Deerfield Management

Joel S. Marcus

Chairman, Chief Executive, and Founder, Alexandria Real Estate Equities, Inc., Alexandria Venture Investments

David Mitchell

Partner, GMMB

Richard Schilsky, M.D.

Chief Medical Officer, American Society of Clinical Oncology

BOARD OF DIRECTORS

Pennie Abramson, Ph.D. (h.c.)

President's Circle, The Weizmann Institute of Science

Carolyn "Bo" Aldige

President & Founder, Prevent Cancer Foundation

Anna Barker, Ph.D.

Professor & Director, Transformative Healthcare Networks, Arizona State University

Christopher W. Hansen

President, American Cancer Society Cancer Action Network

Sherry Lansing

Chief Executive Officer, The Sherry Lansing Foundation

Catherine Ann Stevens, J.D.

Partner, Mayer Brown LLP

Mary Woolley

President, Research! America

Robert C. Young, M.D.

President, RCYMedicine

Thank you to all of the *Friends* staff and collaborators who contribute to our work.

A special thanks to:

Jeff Allen, Ph.D., Executive Director

Ryan Hohman, J.D., Managing Director, Policy and Public Affairs

Heather Chaney, Managing Director, Program Administration

Berrett Stradford, Director, External Affairs

Samantha Roberts, Ph.D., Director, Scientific Affairs

Marina Kozak, Ph.D., Science Policy Analyst

Mark Stewart, Ph.D., Science Policy Analyst

Michael Shea, Policy Research Associate

Joe Patterson, Public Affairs Associate **Alexi Turbow,** Public Affairs Associate

Linda Ostermann, Administrative Coordinator

Supporters

INNOVATORS

Alexandria Real Estate Equities Inc / Alexandria Venture Investments

Amgen

AstraZeneca

Bayer HealthCare

Bristol-Myers Squibb Company

Celgene Corporation

Eli Lilly and Company

Genentech

Janssen Pharmaceuticals, Inc.

Marlene and Fred Malek

Merck & Co., Inc.

Novartis Pharmaceuticals

Corporation

Pfizer Inc

PhRMA

Ellen and Gerry Sigal

Takeda Oncology

CHAMPIONS

Abbvie

The Abramson Family Foundation

American Association for Cancer

Research

American Cancer Society

American Society of Clinical Oncology

Boehringer Ingelheim Pharmaceuticals

EMD Serono

Foundation for the National Institutes

of Health

Foundation Medicine Inc.

Gilead

Ken and Virginia Grunley

Helsinn Therapeutics

Illumina

Johnson & Johnson

The Kovler Foundation – Peter and

Judy Kovler

Onyx Pharmaceuticals Inc.

Pharmacyclics Inc.

Resnick Family Foundation, Inc.

PARTNERS

The Rona and Jeffrey Abramson Foundation

ADP Foundation, Inc.

Association of American Cancer Institutes

Battelle

Burroughs Wellcome Fund

Greenleaf Health LLC

Interstate Hotels and Resorts

Lionsgate

The Meltzer Group

Miller & Long Company, Inc.

National Patient Advocate

Foundation

Prevision Policy

The Abe & Kathryn Selsky

Foundation Inc.

Klara and Larry Silverstein

Vertex Pharmaceuticals

A note from the Executive Director

On behalf of Friends of Cancer Research, I would like to thank all of our supporters and collaborators for your steadfast commitment to our mission. We've made great strides in developing new models to enhance science and innovation.

As we embark on our 20th year, we look forward to continuing partnerships built on cutting-edge science to create solutions that will change the cancer landscape.

Your support is vital to ensuring this work can continue.

With great appreciation,

Jeff Allen, Ph.D., Executive Director, Friends of Cancer Research

Supporters

ADVOCATES

Miriam and Sandford Ain Jeff Allen and Kevin Kenney

Anna Barker Grace Bender

The Honorable and Mrs. Stuart Bernstein

Harold Beznos

Biotechnology Industry Organization

Katherine and David Bradley Henry and Rachel Brem

C.R. Bard, Inc. Marcia Carlucci CBS Corporation

CDW

The Honorable William and Mrs. Janet

Cohen

Dana-Farber Cancer Institute

Deerfield

Dick and Betsy DeVos Mr. and Mrs. Richard Dubin

Edelman

Alvin and Joan Einbender

Eplus, Inc.

Diana and Michael David Epstein

Suellen Estrin

Lucy Fisher and Doug Wick Robert and Shari Friedman Norma Lee and Morton Funger - The Funger Foundation Inc.

General Dynamics

The George Washington University
The Honorable Joseph and Mrs. Alma

Gildenhorn

Jan and Ronald Greenberg Herbert Family Foundation

Ryan Hohman & Bradford Rathgeber

Kids v Cancer Annette Kirshner

Klein Financial Corporation

Sherry Lansing

Leukemia & Lymphoma Society

Lockton Companies, Inc.
Fred and Britlan Malek
Joel and Deborah Meisel
Alan and Amy Meltzer
Milken Family Foundation

MK & A

Moffitt Cancer Center & Research Institute

Barbara Moser

National Pharmaceutical Council

Michelle and Chris Olson

OSU - The James Cancer Hospital Otsuka America Pharmaceutical, Inc. Suzy and Bob Pence

Peregrine Pharmaceuticals, Inc. Edwin and Linda Phelps Leland and Mary Pillsbury

Research!America

Catherine B. Reynolds Foundation Mace and Joyce Rothenberg

Vicki and Roger Sant

Sidney Kimmel Comprehensive Cancer Center

at Johns Hopkins University

Annie Simonian Totah Mr. and Mrs. Albert H. Small

Robert H. Smith Family Foundation

Paul G. Stern Catherine Stevens Michael and Leslie Tive

University of Kansas Cancer Center

University of Maryland Greenbaum Cancer

Center

University of Pittsburgh Cancer Institute

University of Texas MD Anderson Cancer Center

George Vande Woude

Andy and Madelyn von Eschenbach

Vornado - Charles E. Smith

Sharon Weiss

Lynne Zydowsky / Zydowsky Consultants

PATRONS

John Adelman Susan Allen

Shalom Baranes Steven and Shari Bloom

Abigail Blunt

Susan and Dixon Butler Bridget Caracciolo

CEO Roundtable on Cancer

Heather Chaney

Dr. Tony and Robyn Coles

Roger Cossack and Jane

Hannaway Sevasti Dames Susan Davis Ann Dayton Anita Dayton Chip Diggins

Richard and Judy Doling

Samia Farouki FasterCures Joel and Barbara Finkelstein

Stuart Geller Gretchen Gorog

Ira and Judith Gottfried

Anne Grady

Leonard Greenberg Gerard and Pamela Heiber T. Patrick and Ann Marie Hill

Wilhemina Holladay Jacinta Hurley

Gail and Benjamin Jacobs

Dianne Kay

Frank and Cathy Keating

Debra Kirshner Marina Kozak

Brendan and Leanna Lalor Climis and Carol Lascaris

Paul Lewis

Tom and Bonnie Miller
David and Nicole Mitchell

Amy Muhlberg Mary Ann and Scott Nordheimer

Melanie and Larry Nussdorf

Linda Ostermann Joe Patterson Geraldine Pilzer Pauline Randall Renay Regardie

William Regardie Living Trust

Samantha Roberts

Mark and Elizabeth Rogers Eric and Kimberly Rubin Genny and Fred Ryan Matthew and Lynne Shank

Margaret Shannon Mary Singer Berrett Stradford

Courtney Straus
Carl Striler

Alexi Turbow

University of Miami Sylvester Comprehensive Cancer Center

Daniel and Ann Von Hoff

Geoff Wahl

Marilyn and Hal Weiner Robert & Terri Weiss

Ambassador C. Howard Wilkins

Myles Wittenstein

Li Yan

Robert C. Young Nancy Zirkin

In-Kind

Alston + Bird Deerfield Institute

GCS. Inc.

SIGAL Construction The West Foundation